The European Medicines Agency has recommended the AstraZeneca/Daiichi Sankyo cancer drug Enhertu for non-small cell lung cancer. The EMA based its recommendation on data showing Enhertu reduced tumors by 49% in patients who were previously treated for lung cancer. (Reuters)
Amgen is trying to catch up to Novo Nordisk and Eli Lilly in the obesity space. The company is banking on its “platform approach” and “broad optionality” as it awaits Phase II trial results for two candidates. (Endpoints News)
Johnson & Johnson is embarking on a rebranding effort, which will include a logo that replaces the signature script it has used since 1887. The company hopes to highlight its focus on pharma and medical devices in the wake of the spinoff of its consumer health arm. (STAT)
A wide partisan divide on COVID-19 boosters remains among Americans. While three in five voters plan to receive the updated booster, only 39% of Republicans do. (Politico)
MDMA-assisted therapy is effective in alleviating symptoms of PTSD, according to MAPS Public Benefit Corporation. The company, which develops prescription psychedelics, plans to submit trial results to the Food and Drug Administration. (The New York Times)
